Hybrid histone deacetylase kinase inhibitor potentiates venetoclax induced cell death in chronic lymphocytic leukemia (2025)
- Authors:
- USP affiliated authors: LOTUFO, LETICIA VERAS COSTA - ICB ; PARISE FILHO, ROBERTO - FCF ; MACHADO NETO, JOÃO AGOSTINHO - ICB ; GARNIQUE, ANALÍ DEL MILAGRO BERNABÉ - ICB ; CARLOS, JORGE ANTONIO ELIAS GODOY - ICB ; PARDUCCI, NATÁLIA SUDAN - ICB ; WAITMAN, KAROLINE DE BARROS - FCF
- Unidades: ICB; FCF
- DOI: 10.1016/j.htct.2025.103757
- Subjects: LEUCEMIA; PRODUTOS NOVOS; FÁRMACOS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Hematology, Transfusion and Cell Therapy
- ISSN: 2531-1379
- Volume/Número/Paginação/Ano: v. 47, n. 2, p. 1-5 art. 103757, 2025
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by
-
ABNT
GARNIQUE, Anali Del Milagro Bernabe et al. Hybrid histone deacetylase kinase inhibitor potentiates venetoclax induced cell death in chronic lymphocytic leukemia. Hematology, Transfusion and Cell Therapy, v. 47, n. 2, p. 1-5 art. 103757, 2025Tradução . . Disponível em: https://dx.doi.org/10.1016/j.htct.2025.103757. Acesso em: 18 jun. 2025. -
APA
Garnique, A. D. M. B., Carlos, J. A. E. G., Parducci, N. S., Tavares, M. T., Waitman, K. de B., Lima, K., et al. (2025). Hybrid histone deacetylase kinase inhibitor potentiates venetoclax induced cell death in chronic lymphocytic leukemia. Hematology, Transfusion and Cell Therapy, 47( 2), 1-5 art. 103757. doi:10.1016/j.htct.2025.103757 -
NLM
Garnique ADMB, Carlos JAEG, Parducci NS, Tavares MT, Waitman K de B, Lima K, Lotufo LVC, Parise Filho R, Machado Neto JA. Hybrid histone deacetylase kinase inhibitor potentiates venetoclax induced cell death in chronic lymphocytic leukemia [Internet]. Hematology, Transfusion and Cell Therapy. 2025 ; 47( 2): 1-5 art. 103757.[citado 2025 jun. 18 ] Available from: https://dx.doi.org/10.1016/j.htct.2025.103757 -
Vancouver
Garnique ADMB, Carlos JAEG, Parducci NS, Tavares MT, Waitman K de B, Lima K, Lotufo LVC, Parise Filho R, Machado Neto JA. Hybrid histone deacetylase kinase inhibitor potentiates venetoclax induced cell death in chronic lymphocytic leukemia [Internet]. Hematology, Transfusion and Cell Therapy. 2025 ; 47( 2): 1-5 art. 103757.[citado 2025 jun. 18 ] Available from: https://dx.doi.org/10.1016/j.htct.2025.103757 - Hybrid histone deacetylase-kinase inhibitor potentiates venetoclax-induced cell death in chronic lymphocytic leukemia
- Purine-derived Phenylhydroxamate compounds induces cell death in hematological neoplasm models
- Purine-derived phenylhydroxamate compounds reduce cell viability and modulate HDAC activity in hematological neoplasm models
- Exploring the dual role of SIVA1 in cancer biology
- Design and synthesis of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment
- A novel HDAC inhibitor potentiates Venetoclax-induced apoptosis in acute myeloid leukemia cells
- Enhancing venetoclax efficacy in leukemia through association with HDAC inhibitors
- New kinase and HDAC hybrid inhibitors: recent advances and perspectives
- Design of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment
- HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents
Informações sobre o DOI: 10.1016/j.htct.2025.103757 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
